Kaname Ohyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kaname Ohyama has a total of 254 co-authors. Here are the top co-authors by number of shared publications:
- Naoya Kishikawa
Department of Analytical Chemistry for Pharmaceutics, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
23 shared publications - Naotaka Kuroda
Department of Analytical Chemistry for Pharmaceuticals, Course of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
22 shared publications Mikiro Nakashima
14 shared publications- Nozomi Aibara
Department of Pharmacy Practice, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
12 shared publications Kenichiro Nakashima
Nagasaki University
10 shared publicationsNozomi Aibara
Graduate School of Biomedical Sciences, Nagasaki University
10 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 283
Development and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes
- 8 September 2026
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 283
Open AccessDevelopment and application of antibody framework region-targeted cross-linking mass spectrometry for epitope screening within patient-derived immune complexes
- 26 August 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (10)
Development and validation of machine learning model for selecting the optimal population pharmacokinetic model for vancomycin
- 26 August 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (10)
Development and validation of machine learning model for selecting the optimal population pharmacokinetic model for vancomycin
- 15 October 2025
- Published by Springer Nature
- Vol. 2980, 189-197
Identification of Disease Characteristic Immune Complex Antigens
Comprehensive identification and profiling of antigens in immune complexes (IC antigens) is useful to provide insights into pathophysiology and could form the basis for novel diagnostic and treatment strategies for many immune-related diseases. Immune complexome analysis is the method for comprehensively identifying and profiling IC antigens in biological fluids (such as serum, cerebrospinal fluid, urine, and saliva). Here, we describe IC-antigens detection method; specifically, ICs in biological fluids are captured by using Protein G- or Protein A-coated beads, are subjected to papain-digestion elution and tryptic digestion, and are analyzed by nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS).
- 15 October 2025
- Published by Springer Nature
- Vol. 2980, 189-197
Identification of Disease Characteristic Immune Complex Antigens
Comprehensive identification and profiling of antigens in immune complexes (IC antigens) is useful to provide insights into pathophysiology and could form the basis for novel diagnostic and treatment strategies for many immune-related diseases. Immune complexome analysis is the method for comprehensively identifying and profiling IC antigens in biological fluids (such as serum, cerebrospinal fluid, urine, and saliva). Here, we describe IC-antigens detection method; specifically, ICs in biological fluids are captured by using Protein G- or Protein A-coated beads, are subjected to papain-digestion elution and tryptic digestion, and are analyzed by nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS).
- 29 September 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (10) , 1-8
Identification and characterization of salivary immune complex antigens in oral cancer
Objectives This study aims to identify antigens incorporated into immune complexes that are associated with oral cancer pathogenesis and to determine their potential clinical applications. Materials and methods In this study, immune complexome analysis was performed on saliva samples from 66 patients with oral cancer and 40 controls. Immune complexome analysis is an original method for the comprehensive identification of immune complex antigens in body fluids by liquid chromatography-mass spectrometry. Results We identified 24 IC-antigens that were significantly elevated in early-stage oral cancer compared with the controls, suggesting their potential as indicators for oral cancer. Four IC-antigens (ALOX5, B3GALT6, LAMA4, POLA1) were expressed at significantly higher levels in advanced-stage disease, indicating their involvement in cancer progression. Survival analysis revealed that high levels of POLA1 were associated with lower survival rates. Most of these proteins were reported to be involved in cancer progression and cell proliferation. Conclusion These findings support the formation of disease-characteristic immune complexes in oral cancer and highlight the potential of immune complexome analysis in saliva for understanding oral cancer pathogenesis and therapeutic targets.
- 29 September 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (10) , 1-8
Identification and characterization of salivary immune complex antigens in oral cancer
Objectives This study aims to identify antigens incorporated into immune complexes that are associated with oral cancer pathogenesis and to determine their potential clinical applications. Materials and methods In this study, immune complexome analysis was performed on saliva samples from 66 patients with oral cancer and 40 controls. Immune complexome analysis is an original method for the comprehensive identification of immune complex antigens in body fluids by liquid chromatography-mass spectrometry. Results We identified 24 IC-antigens that were significantly elevated in early-stage oral cancer compared with the controls, suggesting their potential as indicators for oral cancer. Four IC-antigens (ALOX5, B3GALT6, LAMA4, POLA1) were expressed at significantly higher levels in advanced-stage disease, indicating their involvement in cancer progression. Survival analysis revealed that high levels of POLA1 were associated with lower survival rates. Most of these proteins were reported to be involved in cancer progression and cell proliferation. Conclusion These findings support the formation of disease-characteristic immune complexes in oral cancer and highlight the potential of immune complexome analysis in saliva for understanding oral cancer pathogenesis and therapeutic targets.
- 27 August 2025
- Published by Elsevier in Clinical Immunology
- Vol. 281, 110591
Identification of immune complex antigens that are detected prior to early rheumatoid arthritis symptoms and increase with disease progression: Comprehensive serum immune complexome analysis to identify candidate disease biomarkers in health checkup cohort study
- 27 August 2025
- Published by Elsevier in Clinical Immunology
- Vol. 281, 110591
Identification of immune complex antigens that are detected prior to early rheumatoid arthritis symptoms and increase with disease progression: Comprehensive serum immune complexome analysis to identify candidate disease biomarkers in health checkup cohort study
- 24 December 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (1) , 47-49
Authors’ Reply to Noguchi et al. Comment on: “Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors Used in Patients with Diabetes and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database”
- 24 December 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (1) , 47-49
Authors’ Reply to Noguchi et al. Comment on: “Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors Used in Patients with Diabetes and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database”
- 15 December 2024
- Published by Elsevier in Clinical Biochemistry
- Vol. 135, 110865
Immune complexome analysis reveals an autoimmune signature predictive of COVID-19 severity
- 15 December 2024
- Published by Elsevier in Clinical Biochemistry
- Vol. 135, 110865
Immune complexome analysis reveals an autoimmune signature predictive of COVID-19 severity
- 23 October 2024
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (1) , 129-137
Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)
Purpose SN-38, the active metabolite of irinotecan, may cause adverse events necessitating treatment discontinuation and management. Diarrhea, which is treated with loperamide, is one such event. However, loperamide may delay SN-38 elimination, causing more adverse events. Therefore, understanding the adverse events caused by symptomatic drugs is crucial for safe drug therapy. This study aimed to assess the association between loperamide and irinotecan-induced adverse events. Methods We analyzed data up to December 2022 from VigiBase, the World Health Organization’s adverse event database. The study used reporting odds ratios (RORs) to evaluate the associations between concomitant medications and irinotecan-induced adverse events. Fisher’s exact probability test was used to analyze the adverse events. Logistic regression analysis was performed to identify associated adverse event signals. Results Of the 32,520,983 cases analyzed, 57,454 involved the use of irinotecan. Among these, 1589 (2.8%) patients were co-treated with loperamide. Signals for neutropenia (ROR 1.37, 95% confidence interval (CI) 1.20–1.57, p < 0.001), anemia (ROR 1.81, 95% CI 1.43–2.30, p < 0.001), and alopecia (ROR 1.89, 95% CI 1.30–2.74, p < 0.01) were detected with concomitant loperamide. Multivariate logistic regression analysis confirmed that concomitant loperamide use was associated with signals for neutropenia, anemia, and alopecia. Conclusion Our results suggest that loperamide increases the risk of irinotecan-induced adverse events and enhances irinotecan toxicity. The study methodology may be useful for predicting adverse event risk when choosing symptomatic therapy drugs during irinotecan use.
- 23 October 2024
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (1) , 129-137
Evaluating the impact of loperamide on irinotecan-induced adverse events: a disproportionality analysis of data from the World Health Organization pharmacovigilance database (VigiBase)
Purpose SN-38, the active metabolite of irinotecan, may cause adverse events necessitating treatment discontinuation and management. Diarrhea, which is treated with loperamide, is one such event. However, loperamide may delay SN-38 elimination, causing more adverse events. Therefore, understanding the adverse events caused by symptomatic drugs is crucial for safe drug therapy. This study aimed to assess the association between loperamide and irinotecan-induced adverse events. Methods We analyzed data up to December 2022 from VigiBase, the World Health Organization’s adverse event database. The study used reporting odds ratios (RORs) to evaluate the associations between concomitant medications and irinotecan-induced adverse events. Fisher’s exact probability test was used to analyze the adverse events. Logistic regression analysis was performed to identify associated adverse event signals. Results Of the 32,520,983 cases analyzed, 57,454 involved the use of irinotecan. Among these, 1589 (2.8%) patients were co-treated with loperamide. Signals for neutropenia (ROR 1.37, 95% confidence interval (CI) 1.20–1.57, p < 0.001), anemia (ROR 1.81, 95% CI 1.43–2.30, p < 0.001), and alopecia (ROR 1.89, 95% CI 1.30–2.74, p < 0.01) were detected with concomitant loperamide. Multivariate logistic regression analysis confirmed that concomitant loperamide use was associated with signals for neutropenia, anemia, and alopecia. Conclusion Our results suggest that loperamide increases the risk of irinotecan-induced adverse events and enhances irinotecan toxicity. The study methodology may be useful for predicting adverse event risk when choosing symptomatic therapy drugs during irinotecan use.
- 14 October 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (10) , 761-771
Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database
Background and Objectives Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently become a standard treatment for heart failure and renal failure. The number of patients using these drugs is expected to increase further. However, no adverse drug event profiles have been published for the use of SGLT2i in patients without diabetes. To analyze and clarify the differences in adverse event profiles associated with the use of SGLT2i in patients with diabetes or heart failure using the Japanese Adverse Drug Event Report (JADER) database, a Japanese reporting system for adverse events. Methods The JADER database, containing reports submitted between April 2004 and January 2024, was used. Our study focused on patients with diabetes or heart failure, analyzing adverse events associated with empagliflozin and dapagliflozin. The reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated for signal detection. Results We identified risks of adverse drug events such as ketoacidosis, urinary tract infection, dehydration, and acidosis in both patient groups. However, the risks of cerebral infarction and ischemic heart disease were identified only in patients with diabetes, while risks of renal dysfunction, hypoglycemia, and sepsis were identified only in those with heart failure. Conclusion Adverse events should be managed appropriately for patients using SGLT2i, as the adverse event profiles differ between those with diabetes and those with heart failure. Understanding these differences is crucial for improving patient safety and optimizing treatment outcomes.
- 14 October 2024
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 44 (10) , 761-771
Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database
Background and Objectives Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently become a standard treatment for heart failure and renal failure. The number of patients using these drugs is expected to increase further. However, no adverse drug event profiles have been published for the use of SGLT2i in patients without diabetes. To analyze and clarify the differences in adverse event profiles associated with the use of SGLT2i in patients with diabetes or heart failure using the Japanese Adverse Drug Event Report (JADER) database, a Japanese reporting system for adverse events. Methods The JADER database, containing reports submitted between April 2004 and January 2024, was used. Our study focused on patients with diabetes or heart failure, analyzing adverse events associated with empagliflozin and dapagliflozin. The reporting odds ratio (ROR) and 95% confidence interval (CI) were calculated for signal detection. Results We identified risks of adverse drug events such as ketoacidosis, urinary tract infection, dehydration, and acidosis in both patient groups. However, the risks of cerebral infarction and ischemic heart disease were identified only in patients with diabetes, while risks of renal dysfunction, hypoglycemia, and sepsis were identified only in those with heart failure. Conclusion Adverse events should be managed appropriately for patients using SGLT2i, as the adverse event profiles differ between those with diabetes and those with heart failure. Understanding these differences is crucial for improving patient safety and optimizing treatment outcomes.